Medical Devices

Flagship Communities REIT wins a top award for the fifth year, but the real story is its model for turning overlooked properties into vibrant, amenity-rich communities.

For millions, the 'why' behind infertility remains a mystery. New genomic mapping tech is finally providing answers, changing the landscape of family planning.

Major academic centers no longer hold a monopoly on medical breakthroughs. A look at how community networks are democratizing cutting-edge cancer research.

Famed design firm Whipsaw is expanding beyond blueprints, hiring Roomba launch veteran Nancy Smith to build a new practice aimed at solving a key industry flaw.

A $4M grant for a Parkinson's drug isn't just charity; it's a strategic bet on a new era of medicine, where philanthropy acts as the catalyst for the next big cure.

Philip Morris International holds its dividend steady, signaling stability to investors. But can consistent payouts mask the risks of its smoke-free revolution?

A key clinical trial completion in Japan signals a major shift in prostate cancer care, heralding the arrival of advanced PSMA-targeted theranostics.

A Swedish firm's novel cell therapy is the first of its kind in Europe, challenging the grim prognosis of pancreatic cancer and testing a new model for biotech.

In under two years, Cynosure Lutronic's XERF device has tripled its adoption rate, signaling a major shift in the multi-billion dollar aesthetics industry.

As Kewaunee Scientific preps its year-end report, all eyes are on whether its bold Nu Aire acquisition can translate revenue gains into long-term profit.

Our digital lives create a mountain of e-waste. As leaders meet to tackle the issue, the real story is in the data, security, and untapped billions.

A new partnership between Daybreak and VHSS isn't just about a new device; it’s a durable model for delivering resilient healthcare solutions to veterans.

Millions suffer from chronic sciatica with few good options. A small biotech is betting on a novel, non-opioid drug to fix the problem, not just mask it.

Beacon Biosignals is merging AI-driven brain monitoring with home sleep testing, creating a powerful new platform that could redefine neurological diagnostics.

A market set to triple, driven by gene-level therapies, promises a revolution for children with rare epilepsies. But can our systems deliver this hope?

Cymbiotika just named co-founder Durana Elmi its creative and experiential chief. It’s more than a title—it’s a blueprint for the future of wellness.

At EHA 2026, Parexel isn't just presenting data; it's unveiling a bold new strategy to fix a broken system and accelerate life-saving blood cancer drugs.

The Ohio manufacturer's management buyout signals a shift from private equity cycles to long-term agility in a booming precision components market.

A new study reveals the biggest planning mistake in enterprise IT is rigid strategy. For companies betting on digital transformation, adaptability is now survival.

A groundbreaking partnership between Servier and n-Lorem Foundation blends pharma R&D muscle with non-profit agility to develop ASO therapies for the rarest of diseases.